Iveda files supplement to register 235,625 warrants

Rhea-AI Filing Summary

Iveda Solutions, Inc. files a Prospectus Supplement No. 14 to the March 31, 2022 prospectus to include its Form 10-K and to cover warrants to purchase 235,625 shares of common stock at a strike price of $34.00 per share held by stockholders identified in the prospectus.

Key Figures

Registered warrants: 235,625 shares Exercise price: $34.00 per share Prospectus supplement date: April 1, 2026 +2 more

5 metrics

Registered warrants 235,625 shares warrants to purchase common stock

Exercise price $34.00 per share warrants exercisable at this price

Prospectus supplement date April 1, 2026 date of Prospectus Supplement No. 14

Incorporated report Form 10-K (Dec 31, 2025) Form 10-K attached and incorporated by reference

Registration number 333-261963 registration number on cover

Key Terms

Prospectus Supplement, warrants, Form 10-K

3 terms

Prospectus Supplement regulatory

"This Prospectus Supplement supplements and amends the Prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

warrants financial

"warrants to purchase 235,625 shares at $34.00 per share"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Form 10-K regulatory

"include the information set forth in our Annual Report on Form 10-K for the period ended December 31, 2025"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the IVDA Prospectus Supplement No. 14 register?

It registers warrants to purchase 235,625 shares of common stock. The supplement covers warrants exercisable at $34.00 per share and incorporates the company's Form 10-K for the year ended December 31, 2025, filed March 31, 2026.

Who benefits from proceeds of the sales covered by the IVDA supplement?

The supplement references warrants held by stockholders, not direct company proceeds. The filing states these are warrants held by stockholders identified in the prospectus; the prospectus language governs whether the issuer receives any proceeds.

When was this Prospectus Supplement for IVDA dated?

The Prospectus Supplement is dated April 1, 2026. It amends the Prospectus effective March 31, 2022 and attaches the Form 10-K filed on March 31, 2026 for the year ended December 31, 2025.

What exercise price applies to the warrants in the IVDA supplement?

The warrants are exercisable at $34.00 per share. The supplement states warrants to purchase up to 235,625 shares at an exercise price of $34.00 per share.

Does the supplement change the risk factors for IVDA shareholders?

It instructs readers to review existing risk factors in the prospectus. The supplement advises reading the "Risk Factors" starting on page 6 of the prospectus and incorporates the Form 10-K for updated disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 06:42 PM EDT Learn about SEC filing dates

Prospectus Supplement No. 14	Filed Pursuant to Rule 424(b)(3)
(To Prospectus effective March 31, 2022)	Registration No. 333-261963

235,625 Shares of Common Stock

Warrants to Purchase up to 235,625 Shares of Common Stock

This Prospectus Supplement supplements and amends the Prospectus dated March 28, 2022 and effective March 31, 2022 (the “Prospectus”), relating to the warrants to purchase 235,625 shares at $34.00 per share of common stock of Iveda Solutions, Inc. (the “Company”) by the stockholders identified in the Prospectus.

This Prospectus Supplement is being filed to include the information set forth in our Annual Report on Form 10-K for the period ended December 31, 2025, filed by the Company with the Securities and Exchange Commission on March 31, 2026 (the “Form 10-K”). The Form 10-K is attached hereto.

This Prospectus Supplement is not complete without and may not be delivered or utilized except in connection with the Prospectus, including any supplements and amendments thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, which is to be delivered with this Prospectus Supplement. This Prospectus Supplement is qualified by reference to the Prospectus, except to the extent that the information in this Prospectus Supplement updates or supersedes the information contained in the Prospectus, including any supplements and amendments thereto.

See “Risk Factors” beginning on page 6 of the Prospectus to read about factors you should consider before buying shares of our common stock.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of the Prospectus. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is April 1, 2026